Clinical trial · Observational
Study on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics and Its Clinical Relevance
NCT07783971CI-TRIAL-00123736recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to uncover the characteristics of the fungal flora in non-small cell lung cancer, and to investigate the relationship between pulmonary fungi and the various pathological subtypes, stages, clinical features of non-small cell lung cancer, as well as patient prognosis. It seeks to provide new perspectives for a comprehensive understanding of non-small cell lung cancer, as well as new approaches for its early diagnosis and prognosis assessment.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fungal Diseases | — | UNRESOLVED | — |
| Lung Cancer (NSCLC) | Malignant Lung Neoplasm | CURATED_EXACT | 0.85 |
| Microbioata | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Lung cancer group
- description
- The samples included in this group were lung cancer tissues.
- label
- Normal lung tissue group
- description
- The samples included in this group were normal lung tissues.
Primary outcomes (1)
- measure
- the fungal microbial environment
- timeFrame
- baseline, pre-surgery
- description
- Different fungal microbial environments were observed in different parts of lung tissue.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: Non-small cell lung cancer was diagnosed by biopsy before operation, frozen pathology during operation or paraffin section after operation; The patients were 30 to 80 years old; No chemotherapy, radiotherapy, targeted therapy or immunotherapy were given before operation; Exclusion Criteria: Patients who do not meet the inclusion criteria; Combined with primary malignant tumor of other systems or recurrence of lung cancer, combined with immunodeficiency disease; Acute exacerbation of chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis with infection, tuberculosis and pneumoconiosis; recent use of antifungal drugs; Basic clinical information (such as pathological type, clinical stage and treatment plan) cannot be obtained;
References
Publications (3)
- BACKGROUNDDohlman AB, Klug J, Mesko M, Gao IH, Lipkin SM, Shen X, Iliev ID. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell. 2022 Sep 29;185(20):3807-3822.e12. doi: 10.1016/j.cell.2022.09.015. PMID 36179671
- BACKGROUNDLiu NN, Yi CX, Wei LQ, Zhou JA, Jiang T, Hu CC, Wang L, Wang YY, Zou Y, Zhao YK, Zhang LL, Nie YT, Zhu YJ, Yi XY, Zeng LB, Li JQ, Huang XT, Ji HB, Kozlakidis Z, Zhong L, Heeschen C, Zheng XQ, Chen C, Zhang P, Wang H. The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells. Cancer Cell. 2023 Nov 13;41(11):1927-1944.e9. doi: 10.1016/j.ccell.2023.08.012. Epub 2023 Sep 21. PMID 37738973
- BACKGROUNDNarunsky-Haziza L, Sepich-Poore GD, Livyatan I, Asraf O, Martino C, Nejman D, Gavert N, Stajich JE, Amit G, Gonzalez A, Wandro S, Perry G, Ariel R, Meltser A, Shaffer JP, Zhu Q, Balint-Lahat N, Barshack I, Dadiani M, Gal-Yam EN, Patel SP, Bashan A, Swafford AD, Pilpel Y, Knight R, Straussman R. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell. 2022 Sep 29;185(20):3789-3806.e17. doi: 10.1016/j.cell.2022.09.005. PMID 36179670